Full coverage: healthcare

Theya Lingerie was founded by Ciara Donlon to provide women with post-surgery underwear. Selling across Europe and the US, it has now run out of road and its rescue plan through Scarp could lead to a sale.

The French nursing home group, which has a leading position in Ireland, is facing insolvency early next year if it can’t convince investors to refinance it for the second time since a scandal erupted last January.

The Irish unit of the US-listed specialist waste collector, which holds the contract for the public health system, has achieved record margins in the past two years.

Irregularities uncovered in France have shaken Orpea, the multinational group now dominating Ireland's nursing home industry. This investigation draws from inside sources and dozens of inspection reports to assess what the scandal means for its hundreds of residents and its expansion plans here.

Orpea had become a Paris stock market darling and a world leader in private care but it all came crashing down over the course of this year. A two-part investigation explores the impact on its recent drive into Ireland.

The HSE halted payments to the Mater Private amid concerns that it was being billed for hefty intercompany interest bills paid to a Luxembourg entity. The High Court has largely ruled in its favour.

For years, the Irish-headquartered medical supplier Covidien outsourced core functions to the US without paying Vat on transactions including preparations for its acquisition by Medtronic. The company’s successful tax appeal is now going down the legal route.

Online retailers' ability with data is an important reason why they're crushing their bricks-and-mortar retail competition. For this reason and others, it's hard to see offline retail coming back – in fact, healthcare is about to see the same disruption.

John Power and Aerogen are looking to the future with a series of ground-breaking new drug delivery technologies. But to understand that future, you need to understand Power’s past. And that is a remarkable story in itself.

Peter Foley's at-home testing company is scaling at warp speed and became a unicorn last year. But just how did it reach such a hefty valuation so quickly, and what do we know about its underlying financial performance?